Imugene Ltd (ASX:IMU, OTC:IUGNF), a clinical-stage immuno-oncology company based in Australia, has been invited to present at the 42nd annual JP Morgan Healthcare Conference, to be held from January 7 to 11, 2024, in San Francisco.
The company’s managing director and CEO Leslie Chong will present at 2:30pm Pacific time on Tuesday, January 9, 2024 (9:30am AEDT, Wednesday, January 10, 2024).
The presentation can be listened to via an audio-only stream with presentation slides on the JP Morgan website. https://protect-usb.mimecast.com/s/2kBqCWWAmOf5qxAS6cXEW?domain=jpmorgan.metameetings.net
Showcasing technology to a global audience
“This is the second year we have been invited to speak at the JP Morgan Healthcare Conference which is a major honour and rare for an Australian biotechnology company,” Leslie Chong said.
“Following an exciting year for Imugene in 2023, we’re looking forward to showcasing our technology, including our recently acquired azer-cel platform, to a global audience at the event.”
The JP Morgan Healthcare Conference is one of the largest and most prestigious events on the healthcare and biotechnology industry calendar each year, with more than 8,000 investors, senior industry professionals and government officials in attendance at the 2023 event.
IMU is targeting blood cancers with the off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets the CD19 protein, a useful marker of B cell lineage in leukemias and lymphomas as well as some acute myeloid leukemias.